483 related articles for article (PubMed ID: 21886014)
1. Can ¹⁸F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in oesophageal cancer patients? A meta-analysis.
Chen YM; Pan XF; Tong LJ; Shi YP; Chen T
Nucl Med Commun; 2011 Nov; 32(11):1005-10. PubMed ID: 21886014
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
Cheng X; Li Y; Liu B; Xu Z; Bao L; Wang J
Acta Radiol; 2012 Jul; 53(6):615-27. PubMed ID: 22734080
[TBL] [Abstract][Full Text] [Related]
3. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
[TBL] [Abstract][Full Text] [Related]
4. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review.
Kwee RM
Radiology; 2010 Mar; 254(3):707-17. PubMed ID: 20177086
[TBL] [Abstract][Full Text] [Related]
5. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
[TBL] [Abstract][Full Text] [Related]
6. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
[TBL] [Abstract][Full Text] [Related]
7. Assessment of response to neoadjuvant therapy in esophageal cancer: an updated systematic review of diagnostic accuracy of endoscopic ultrasonography and fluorodeoxyglucose positron emission tomography.
Ngamruengphong S; Sharma VK; Nguyen B; Das A
Dis Esophagus; 2010 Apr; 23(3):216-31. PubMed ID: 19515185
[TBL] [Abstract][Full Text] [Related]
8. Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
Moore JL; Subesinghe M; Santaolalla A; Green M; Deere H; Van Hemelrijck M; Lagergren J; Chicklore S; Maisey N; Gossage JA; Kelly M; Baker CR; Davies AR;
Eur Radiol; 2023 May; 33(5):3647-3659. PubMed ID: 36920518
[TBL] [Abstract][Full Text] [Related]
9. Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis.
Wang Y; Zhang C; Liu J; Huang G
Breast Cancer Res Treat; 2012 Jan; 131(2):357-69. PubMed ID: 21960111
[TBL] [Abstract][Full Text] [Related]
10. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy--systematic review.
Westerterp M; van Westreenen HL; Reitsma JB; Hoekstra OS; Stoker J; Fockens P; Jager PL; Van Eck-Smit BL; Plukker JT; van Lanschot JJ; Sloof GW
Radiology; 2005 Sep; 236(3):841-51. PubMed ID: 16118165
[TBL] [Abstract][Full Text] [Related]
11. Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a meta-analysis.
Mghanga FP; Lan X; Bakari KH; Li C; Zhang Y
Clin Breast Cancer; 2013 Aug; 13(4):271-9. PubMed ID: 23714689
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive values of interim
Han S; Kim YI; Woo S; Kim TH; Ryu JS
Ann Nucl Med; 2021 Apr; 35(4):447-457. PubMed ID: 33471289
[TBL] [Abstract][Full Text] [Related]
13. Role of positron emission tomography in the (re-)staging of oesophageal cancer.
Westerterp M; Van Westreenen HL; Sloof GW; Plukker JT; Van Lanschot JJ
Scand J Gastroenterol Suppl; 2006; (243):116-22. PubMed ID: 16782630
[TBL] [Abstract][Full Text] [Related]
14. The predictive value of 18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis.
Cong L; Wang S; Gao T; Hu L
Jpn J Clin Oncol; 2016 Dec; 46(12):1118-1126. PubMed ID: 27702836
[TBL] [Abstract][Full Text] [Related]
15. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Hölscher AH; Dietlein M; Bollschweiler E; Baldus SE; Mönig SP; Metzger R; Schicha H; Schmidt M
Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
[TBL] [Abstract][Full Text] [Related]
16. Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET.
Sloof GW
Best Pract Res Clin Gastroenterol; 2006; 20(5):941-57. PubMed ID: 16997171
[TBL] [Abstract][Full Text] [Related]
17. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography for monitoring response to neoadjuvant therapy in patients with oesophageal and gastro-oesophageal junction carcinoma.
Suttie SA; Welch AE; Park KG
Eur J Surg Oncol; 2009 Oct; 35(10):1019-29. PubMed ID: 19232881
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Value of (18)F-FDG PET/CT in Detecting Local Recurrent Colorectal Cancer: A Pooled Analysis of 26 Individual Studies.
Yu T; Meng N; Chi D; Zhao Y; Wang K; Luo Y
Cell Biochem Biophys; 2015 Jun; 72(2):443-51. PubMed ID: 25737131
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: a meta-analysis.
Hongtao L; Hui Z; Bingshun W; Xiaojin W; Zhiyu W; Shuier Z; Aina H; Yuanjue S; Daliu M; Zan S; Yang Y
Surg Oncol; 2012 Dec; 21(4):e165-70. PubMed ID: 22884956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
